Orchestra Biomed Holdings Inc (OBIO) FinancialsOBIOOrchestra Biomed Holdings Inc

Evaluating the bottom line, Orchestra Biomed Holdings Inc maintains a gross margin of 71.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25404.55%, while the net margin is -22447.47%. These profitability ratios, combined with a Return on Equity (ROE) of -607.32%, provide a clear picture of how effectively OBIO converts its operational activities into shareholder value.

In the context of the broader market, OBIO competes directly with industry leaders such as ZJYL and PROF. With a market capitalization of $357.63M, it holds a leading position in the sector. When comparing efficiency, OBIO's gross margin of 71.21% stands against ZJYL's 24.31% and PROF's 78.41%. Such benchmarking helps identify whether Orchestra Biomed Holdings Inc is trading at a premium or discount relative to its financial performance.

Orchestra Biomed's financial performance shows a significant gross margin of 94.93% in Q1 2025, indicating strong profitability potential despite current losses. The company has also secured $35 million in strategic capital, enhancing its financial stability.